TOS Urges Obese Individuals to Get Vaccinated, Citing High Efficacy
The Obesity Society (TOS) has issued updated guidance on COVID-19 vaccination for individuals with obesity. It urges them to get vaccinated as soon as possible, emphasizing the vaccines' high efficacy in preventing severe disease and death.
TOS's recommendation is backed by research from its members and associated institutions. Studies show that vaccines like Pfizer, Moderna, and Johnson & Johnson are highly effective in individuals with obesity.
The Pfizer vaccine, for instance, demonstrated 95.4% efficacy in this group, with 100% efficacy in older adults. Moderna's vaccine showed 91.2% efficacy in those with severe obesity and 95.8% efficacy in those with obesity. Even the Johnson & Johnson vaccine, with 66.8% efficacy 14 days after the first dose and 65.9% efficacy 28 days after, offers significant protection.
TOS encourages individuals with obesity to accept whichever vaccine is offered, as all approved vaccines have proven equally efficacious in this group. It also supports evidence-based weight management therapies and COVID-19 prevention strategies.
TOS's position is clear: individuals with obesity should prioritize getting vaccinated, as the vaccines available offer substantial protection against severe COVID-19. The society will continue to monitor emerging data and issue updated statements as needed.
Read also:
- Inadequate supply of accessible housing overlooks London's disabled community
- Strange discovery in EU: Rabbits found with unusual appendages resembling tentacles on their heads
- Duration of a Travelling Blood Clot: Time Scale Explained
- Fainting versus Seizures: Overlaps, Distinctions, and Proper Responses
